| [1] |
Pavel M, Oberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31(7): 844-860.
|
| [2] |
Janson ET, Knigge U, Dam G, et al. Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms[J]. Acta Oncol, 2021, 60(7): 931-941.
|
| [3] |
中国临床肿瘤学会神经内分泌肿瘤专家委员会. 中国胃肠胰神经内分泌肿瘤专家共识(2022年版)[J]. 中华肿瘤杂志, 2022, 44(12): 1305-1329.
|
| [4] |
Ramachandran A, Madhusudhan KS. Advances in the imaging of gastroenteropancreatic neuroendocrine neoplasms[J]. World J Gastroenterol, 2022, 28(26): 3008-3026.
|
| [5] |
王杨迪, 宋晨宇, 石思雅, 等. 胃肠胰神经内分泌肿瘤的影像学研究进展[J]. 放射学实践, 2020, 35(9): 1190-1195.
|
| [6] |
Yu R, Wachsman A. Imaging of Neuroendocrine Tumors: Indications, Interpretations, Limits, and Pitfalls[J]. Endocrinol Metab Clin North Am, 2017, 46(3): 795-814.
|
| [7] |
薛冰艳, 柏建安, 朱国琴, 等. 胃肠胰神经内分泌肿瘤的内镜诊治进展[J]. 中华消化内镜杂志, 2021, 38(7): 522-526.
|
| [8] |
Sahani DV, Bonaffini PA, Fernandez-Del Castillo C, et al. Gastroenteropancreatic neuroendocrine tumors: role of imaging in diagnosis and management[J]. Radiology, 2013, 266(1): 38-61.
|
| [9] |
Poltorak-Szymczak G, Budlewski T, Furmanek MI, et al. Radiological Imaging of Gastro-Entero-Pancreatic Neuroendocrine Tumors. The Review of Current Literature Emphasizing the Diagnostic Value of Chosen Imaging Methods[J]. Front Oncol, 2021, 11: 670233.
|
| [10] |
van der Velden DL, Staal FCR, Aalbersberg EA, et al. Prognostic value of CT characteristics in GEP-NET: A systematic review[J]. Crit Rev Oncol Hematol, 2022, 175: 103713.
|
| [11] |
郝辉, 万娅敏, 高剑波. 一站式CT灌注成像联合增强扫描用于胰腺神经内分泌肿瘤[J]. 中国医学影像技术, 2020, 36(1): 91-95.
|
| [12] |
Yuan J, Wang Y, Hu X, et al. Use of dual-layer spectral detector computed tomography in the diagnosis of pancreatic neuroendocrine neoplasms[J]. Eur J Radiol, 2023, 159: 110660.
|
| [13] |
Kamaoui I, De-Luca V, Ficarelli S, et al. Value of CT enteroclysis in suspected small-bowel carcinoid tumors[J]. AJR Am J Roentgenol, 2010, 194(3): 629-633.
|
| [14] |
Chiti G, Grazzini G, Flammia F, et al. Gastroenteropancreatic neuroendocrine neoplasms(GEP-NENs): a radiomic model to predict tumor grade[J]. Radiol Med, 2022, 127(9): 928-938.
|
| [15] |
宋涛, 陆建平, 张倩雯. 人工智能医学影像技术在胰腺神经内分泌肿瘤分级中的应用[J]. 第二军医大学学报, 2020, 41(4): 433-438.
|
| [16] |
Battistella A, Partelli S, Andreasi V, et al. Preoperative assessment of microvessel density in nonfunctioning pancreatic neuroendocrine tumors(NF-PanNETs)[J]. Surgery, 2022, 172(4): 1236-1244.
|
| [17] |
Kim C, Byun JH, Hong SM, et al. A comparison of enhancement patterns on dynamic enhanced CT and survival between patients with pancreatic neuroendocrine tumors with and without intratumoral fibrosis[J]. Abdom Radiol(NY), 2017, 42(12): 2835-2842.
|
| [18] |
Roseland ME, Francis IR, Shampain KL, et al. Gastric neuroendocrine neoplasms: a primer for radiologists[J]. Abdom Radiol(NY), 2022, 47(12): 3993-4004.
|
| [19] |
Shinya T. Malignant Small Bowel Neoplasms: a review of post-contrast multiphasic multidetector computed tomography[J]. J Med Invest, 2022, 69(1/2): 19-24.
|
| [20] |
Picchia S, Terlizzo M, Bali MA. Radiological and histological findings of an asymptomatic ever-increasing neoplasm: The small bowel neuroendocrine tumor(NET)[J]. Curr Probl Cancer, 2020, 44(1): 100495.
|
| [21] |
刘娜, 黄洁惠, 和云雄, 等. 结肠神经内分泌肿瘤的临床及CT影像学表现[J]. 影像研究与医学应用, 2021, 5(1): 24-25.
|
| [22] |
Virarkar M, Gopireddy DR, Morani AC, et al. Rectal neuroendocrine neoplasms: what the radiologists should know[J]. Abdom Radiol(NY), 2022, 47(12): 4016-4031.
|
| [23] |
Bicci E, Cozzi D, Ferrari R, et al. Pancreatic neuroendocrine tumours: spectrum of imaging findings[J]. Gland Surg, 2020, 9(6): 2215-2224.
|
| [24] |
Khanna L, Prasad SR, Sunnapwar A, et al. Pancreatic Neuroendocrine Neoplasms: 2020 Update on Pathologic and Imaging Findings and Classification[J]. Radiographics, 2020, 40(5): 1240-1262.
|
| [25] |
Kim JH, Eun HW, Kim YJ, et al. Pancreatic neuroendocrine tumour(PNET): Staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma[J]. Eur Radiol, 2016, 26(5): 1338-1347.
|
| [26] |
d'Assignies G, Fina P, Bruno O, et al. High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging[J]. Radiology, 2013, 268(2): 390-399.
|
| [27] |
Gultekin MA, Turk HM, Yurtsever I, et al. Apparent Diffusion Coefficient Values for Neuroendocrine Liver Metastases[J]. Acad Radiol, 2021, 28 Suppl 1: S81-S86.
|
| [28] |
Hwang EJ, Lee JM, Yoon JH, et al. Intravoxel incoherent motion diffusion-weighted imaging of pancreatic neuroendocrine tumors: prediction of the histologic grade using pure diffusion coefficient and tumor size[J]. Invest Radiol, 2014, 49(6): 396-402.
|
| [29] |
Budjan J, Sauter EA, Zoellner FG, et al. Diffusion kurtosis imaging of the liver at 3 Tesla: in vivo comparison to standard diffusion-weighted imaging[J]. Acta Radiol, 2018, 59(1): 18-25.
|
| [30] |
Dromain C, de Baere T, Baudin E, et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques[J]. AJR Am J Roentgenol, 2003, 180(1): 121-128.
|
| [31] |
Tirumani SH, Jagannathan JP, Braschi-Amirfarzan M, et al. Value of hepatocellular phase imaging after intravenous gadoxetate disodium for assessing hepatic metastases from gastroenteropancreatic neuroendocrine tumors: comparison with other MRI pulse sequences and with extracellular agent[J]. Abdom Radiol(NY), 2018, 43(9): 2329-2339.
|
| [32] |
Hayoz R, Vietti-Violi N, Duran R, et al. The combination of hepatobiliary phase with Gd-EOB-DTPA and DWI is highly accurate for the detection and characterization of liver metastases from neuroendocrine tumor[J]. Eur Radiol, 2020, 30(12): 6593-6602.
|
| [33] |
Dohan A, El Fattach H, Barat M, et al. Neuroendocrine tumors of the small bowel: evaluation with MR-enterography[J]. Clin Imaging, 2016, 40(3): 541-547.
|
| [34] |
Amzallag-Bellenger E, Soyer P, Barbe C, et al. Diffusion-weighted imaging for the detection of mesenteric small bowel tumours with Magnetic Resonance-enterography[J]. Eur Radiol, 2014, 24(11): 2916-2926.
|
| [35] |
Masselli G, Guida M, Laghi F, et al. Magnetic Resonance of Small Bowel Tumors[J]. Magn Reson Imaging Clin N Am, 2020, 28(1): 75-88.
|
| [36] |
Lo GC, Kambadakone A. MR Imaging of Pancreatic Neuroendocrine Tumors[J]. Magn Reson Imaging Clin N Am, 2018, 26(3): 391-403.
|
| [37] |
Manfredi R, Bonatti M, Mantovani W, et al. Non-hyperfunctioning neuroendocrine tumours of the pancreas: MR imaging appearance and correlation with their biological behaviour[J]. Eur Radiol, 2013, 23(11): 3029-3039.
|
| [38] |
Walczyk J, Sowa-Staszczak A. Diagnostic imaging of gastrointestinal neuroendocrine neoplasms with a focus on ultrasound[J]. J Ultrason, 2019, 19(78): 228-235.
|
| [39] |
Malla S, Kumar P, Madhusudhan KS. Radiology of the neuroendocrine neoplasms of the gastrointestinal tract: a comprehensive review[J]. Abdom Radiol(NY), 2021, 46(3): 919-935.
|
| [40] |
Zhou S, Buxbaum J. Advanced Imaging of the Biliary System and Pancreas[J]. Dig Dis Sci, 2022, 67(5): 1599-1612.
|
| [41] |
Puli SR, Kalva N, Bechtold ML, et al. Diagnostic accuracy of endoscopic ultrasound in pancreatic neuroendocrine tumors: a systematic review and meta analysis[J]. World J Gastroenterol, 2013, 19(23): 3678-3684.
|
| [42] |
Kawamura Diane M., Nolan Tanya D.. 超声诊断学·腹部及浅表器官[M]. 北京: 人民卫生出版社, 2018.
|
| [43] |
Wu W, Chen MH, Yin SS, et al. The role of contrast-enhanced sonography of focal liver lesions before percutaneous biopsy[J]. AJR Am J Roentgenol, 2006, 187(3): 752-761.
|
| [44] |
吴文铭, 陈洁, 白春梅, 等. 中国胰腺神经内分泌肿瘤诊疗指南(2020)[J]. 协和医学杂志, 2021, 12(4): 460-480.
|
| [45] |
Rustagi T, Farrell JJ. Endoscopic diagnosis and treatment of pancreatic neuroendocrine tumors[J]. J Clin Gastroenterol, 2014, 48(10): 837-844.
|
| [46] |
Patel KK, Kim MK. Neuroendocrine tumors of the pancreas: endoscopic diagnosis[J]. Curr Opin Gastroenterol, 2008, 24(5): 638-642.
|
| [47] |
Anderson MA, Carpenter S, Thompson NW, et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas[J]. Am J Gastroenterol, 2000, 95(9): 2271-2277.
|
| [48] |
James PD, Tsolakis AV, Zhang M, et al. Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis[J]. Gastrointest Endosc, 2015, 81(4): 848-856 e841.
|
| [49] |
Sainz-Esteban A, Olmos R, Gonzalez-Sagrado M, et al. Contribution of 111In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours[J]. Nucl Med Commun, 2015, 36(3): 251-259.
|
| [50] |
Cwikla JB, Mikolajczak R, Pawlak D, et al. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs[J]. J Nucl Med, 2008, 49(7): 1060-1065.
|
| [51] |
Balogova S, Talbot JN, Nataf V, et al. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type[J]. Eur J Nucl Med Mol Imaging, 2013, 40(6): 943-966.
|
| [52] |
Sundin A, Arnold R, Baudin E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging[J]. Neuroendocrinology, 2017, 105(3): 212-244.
|
| [53] |
Olsen IH, Langer SW, Federspiel BH, et al.(68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2[J]. Am J Nucl Med Mol Imaging, 2016, 6(1): 59-72.
|
| [54] |
Majala S, Vesterinen T, Seppanen H, et al. Correlation of Somatostatin Receptor 1-5 Expression, [(68)Ga]Ga-DOTANOC, [(18)F] F-FDG PET/CT and Clinical Outcome in a Prospective Cohort of Pancreatic Neuroendocrine Neoplasms[J]. Cancers(Basel), 2021, 14(1): 162.
|
| [55] |
Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT[J]. J Nucl Med, 2007, 48(4): 508-518.
|
| [56] |
Has Simsek D, Kuyumcu S, Turkmen C, et al. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?[J]. J Nucl Med, 2014, 55(11): 1811-1817.
|
| [57] |
Nicolas GP, Schreiter N, Kaul F, et al. Sensitivity Comparison of(68)Ga-OPS202 and(68)Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study[J]. J Nucl Med, 2018, 59(6): 915-921.
|
| [58] |
Menda Y, O'Dorisio TM, Howe JR, et al. Localization of Unknown Primary Site with(68)Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor[J]. J Nucl Med, 2017, 58(7): 1054-1057.
|
| [59] |
Barrio M, Czernin J, Fanti S, et al. The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis[J]. J Nucl Med, 2017, 58(5): 756-761.
|
| [60] |
Ambrosini V, Campana D, Polverari G, et al. Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas[J]. J Nucl Med, 2015, 56(12): 1843-1848.
|
| [61] |
Binderup T, Knigge U, Loft A, et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET[J]. J Nucl Med, 2010, 51(5): 704-712.
|
| [62] |
Rodrigues M, Winkler KK, Svirydenka H, et al. Long-Term Survival and Value of(18)F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with(177)Lu-DOTATATE[J]. Life(Basel), 2021, 11(3): 198.
|
| [63] |
Heimburger C, Veillon F, Taieb D, et al. Head-to-head comparison between(18)F-FDOPA PET/CT and MR/CT angiography in clinically recurrent head and neck paragangliomas[J]. Eur J Nucl Med Mol Imaging, 2017, 44(6): 979-987.
|
| [64] |
Luo Y, Pan Q, Yao S, et al. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study[J]. J Nucl Med, 2016, 57(5): 715-720.
|
| [65] |
Ouvrard E, Mestier LD, Boursier C, et al. F-DOPA PET/CT at the Forefront of Initial or Presurgical Evaluation of Small-Intestine Neuroendocrine Tumors[J]. J Nucl Med, 2022, 63(12): 1865-1870.
|
| [66] |
Hoegerle S, Nitzsche E, Altehoefer C, et al. Pheochromocytomas: detection with 18F DOPA whole body PET--initial results[J]. Radiology, 2002, 222(2): 507-512.
|
| [67] |
Ambrosini V, Tomassetti P, Castellucci P, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours[J]. Eur J Nucl Med Mol Imaging, 2008, 35(8): 1431-1438.
|
| [68] |
Moreau PL, Aveline C, Christin-Maitre S, et al. Role of 68Ga-DOTATOC PET/CT in Insulinoma According to 3 Different Contexts: A Retrospective Study[J]. Clin Nucl Med, 2022, 47(5): 394-401.
|
| [69] |
Wild D, Christ E, Caplin ME, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas[J]. J Nucl Med, 2011, 52(7): 1073-1078.
|
| [70] |
Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States[J]. JAMA Oncol, 2017, 3(10): 1335-1342.
|
| [71] |
Osagiede O, Habermann E, Day C, et al. Factors associated with worse outcomes for colorectal neuroendocrine tumors in radical versus local resections[J]. J Gastrointest Oncol, 2020, 11(5): 836-846.
|
| [72] |
O'Toole D, Delle Fave G, Jensen RT. Gastric and duodenal neuroendocrine tumours[J]. Best Pract Res Clin Gastroenterol, 2012, 26(6): 719-735.
|
| [73] |
Ye L, Lu H, Wu L, et al. The clinicopathologic features and prognosis of esophageal neuroendocrine carcinomas: a single-center study of 53 resection cases[J]. BMC Cancer, 2019, 19(1): 1234.
|
| [74] |
Delle Fave G, O'Toole D, Sundin A, et al. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms [J]. Neuroendocrinology, 2016, 103(2): 119-124.
|
| [75] |
Pape UF, Niederle B, Costa F, et al. ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix(Excluding Goblet Cell Carcinomas)[J]. Neuroendocrinology, 2016, 103(2): 144-152.
|
| [76] |
Shim KN, Yang SK, Myung SJ, et al. Atypical endoscopic features of rectal carcinoids[J]. Endoscopy, 2004, 36(4): 313-316.
|